Access Vascular Inc. (AVI) closed a $22 million series C funding round that it plans to use principally to increase production capacity for its Mimix hydrophilic biomaterial vascular access devices. The company’s catheters are designed to evade identification as foreign bodies, reduce bacterial adhesion and eliminate catheter-related thrombus development.